We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gilead, Polyphor Partner to Discover Macrocycle Drugs
News

Gilead, Polyphor Partner to Discover Macrocycle Drugs

Gilead, Polyphor Partner to Discover Macrocycle Drugs
News

Gilead, Polyphor Partner to Discover Macrocycle Drugs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gilead, Polyphor Partner to Discover Macrocycle Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The collaboration aims to identify and optimize macrocycle molecules addressing challenging biological targets selected by Gilead. Under the terms of the Agreement, Polyphor will receive an upfront payment and research funding, and will be eligible for further milestone payments. In the initial phase of the collaboration Polyphor will apply its entire macrocycle platform consisting of nonpeptidic macrocyles (MacroFinder® ), peptidic macrocycles (PEMfinder® , protein-epitope mimetics) and phage display of PEM-like molecules (PEMphage® ) to generate tractable macrocycle hit families for further optimization. 

Dr. Daniel Obrecht, Chief Scientific Officer of Polyphor said “The collaboration with Gilead is another important milestone for Polyphor. Applying Polyphor’s proprietary macrocycle platform in joint drug discovery projects maximizes the value of the technology for our partners and us. Partnerships with biopharmaceutical companies are a key element of our strategy to realize the full potential of this novel drug class, while focusing our own R&D activities on novel antibiotics and rare respiratory diseases.”

Advertisement